Company intelligence / Profile preview

Corion Biotech

Rome, Italy

Ownership: Private
Development stage: Other

Overview

Corion Biotech is an Italian biotechnology company focused on developing innovative therapies for pregnancy-related disorders, specifically targeting placental health. The company's primary research centers on the therapeutic potential of human chorionic gonadotropin (hCG) to treat and prevent preeclampsia and fetal growth restriction. By leveraging the pro-angiogenic and immunomodulatory properties of hCG, Corion Biotech aims to address significant unmet needs in maternal-fetal medicine. Their lead candidate is a recombinant form of hCG designed to improve placental vascularization and function.

Therapeutic areas: Women's Health
Modalities: BiologicProteinRecombinant protein
Industry: Biotech

Drug pipeline

2 assets

CB-ChMF-11

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Corion Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Corion Biotech.

Explore the full profile